Memo Therapeutics AG Appoints Paul Carter as Chairperson
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market
Improved Revenues Required Before Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is definitely a stock worth checking out, seeing as almost half of all the Biotechs compa
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday.Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million sh
Ironwood Pharmaceuticals Names Sravan Emany to Additional Role of Chief Operating Officer
Ironwood Pharmaceuticals (IRWD) said in a regulatory filing on Thursday that it has appointed Chief Financial Officer Sravan Emany to the additional role of chief operating officer, effective immediat
Ironwood Pharmaceuticals CFO Emany Adds COO Role
By Paul Ziobro Ironwood Pharmaceuticals said Chief Financial Officer Sravan Emany will take on the added role of chief operating officer, effective immediately. Emany, 46, has served as the company'
Express News | Ironwood Pharmaceuticals Appoints Sravan K. Emany As Senior Vice President, Chief Operating Officer, And Chief Financial Officer; Emany Previously Served As Senior Vice President, CFO Since December 2021
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals(IRWD.US) Director Sells US$143.2K in Common Stock
$Ironwood Pharmaceuticals(IRWD.US)$ Director McHugh Julie sold 22,766 shares of common stock on Jun 10, 2024 at an average price of $6.29 for a total value of $143.2K.Source: Announcement What is stat
Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ...
Ironwood Pharmaceuticals(IRWD.US) Director Sells US$517.69K in Common Stock
$Ironwood Pharmaceuticals(IRWD.US)$ Director Moukheibir Catherine sold 80,000 shares of common stock on Jun 6, 7, 2024 at an average price of $6.47 for a total value of $517.69K.Source: Announcement W
Form 144 | Ironwood Pharmaceuticals(IRWD.US) Director Proposes to Sell 144.56K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Ironwood Pharmaceuticals(IRWD.US)$ Director JULIE MCHUGH intends to sell 22,766 shares of its common stock on Jun 10, with a total market value of approximately $144.5
Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing
Catherine Moukheibir, Director, on June 06, 2024, sold 80,000 shares in Ironwood Pharmaceuticals (IRWD) for $517,694. Following the Form 4 filing with the SEC, Moukheibir has control over a total of 4
Form 144 | Ironwood Pharmaceuticals(IRWD.US) Director Proposes to Sell 234.77K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Ironwood Pharmaceuticals(IRWD.US)$ Director Moukheibir Catherine intends to sell 35,574 shares of its common stock on Jun 7, with a total market value of approximately
Form 144 | Ironwood Pharmaceuticals(IRWD.US) Director Proposes to Sell 282.49K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 6, $Ironwood Pharmaceuticals(IRWD.US)$ Director Moukheibir Catherine intends to sell 44,426 shares of its common stock on Jun 6, with a total market value of approximately
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $23
JMP Securities analyst Jason Butler maintains $Ironwood Pharmaceuticals(IRWD.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of
Piper Sandler Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Cuts Target Price to $18
Piper Sandler analyst David Amsellem maintains $Ironwood Pharmaceuticals(IRWD.US)$ with a buy rating, and adjusts the target price from $21 to $18.According to TipRanks data, the analyst has a success
This Insider Has Just Sold Shares In Ironwood Pharmaceuticals
Anyone interested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) should probably be aware that the CEO & Director, Thomas McCourt, recently divested US$436k worth of shares in the company, at an aver
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing
Thomas A McCourt, Director, Chief Executive Officer, on May 20, 2024, sold 67,618 shares in Ironwood Pharmaceuticals (IRWD) for $436,136. Following the Form 4 filing with the SEC, McCourt has control
Express News | Ironwood Pharmaceuticals Inc : Jefferies Cuts Target Price to $14 From $17